OTCM
GTHP
Market cap22mUSD
Oct 08, Last price
0.20USD
1D
-13.01%
1Q
-33.33%
Jan 2017
-62.87%
Name
Guided Therapeutics Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Guided Therapeutics, Inc. is a medical technology firm specializing in the creation of medical devices. Its primary focus is on bringing to market LuViva, an innovative device designed for the non-invasive detection of cervical cancer. This technology excels at identifying both cancerous and precancerous conditions of the cervix in a painless, non-invasive manner, directly at the point of care. LuViva operates by scanning the cervix with light and subsequently analyzing both the reflected and fluorescent light emitted. Established in 1992 and headquartered in Norcross, Georgia, the company was formerly known as SpectRx, Inc. until its rebranding to Guided Therapeutics, Inc. in February 2008.
Key people
Gene S. Cartwright
Chief Executive Officer, Acting Chief Financial Officer, President and Director · since 2014
Mark L. Faupel
Chief Operating Officer, Director · since 2016
Richard L. Fowler
Senior Vice President - Engineering · since 2009
Jonathan M. Niloff
Director · since 2016
John E. Imhoff
Independent Director · since 2006
Independent Director · since 2012
Legal address
C/O The Corporation Trust Company
Corporation Trust Center
1209 Orange Street
Wilmington, DE 19801
US
Corporation Trust Center
1209 Orange Street
Wilmington, DE 19801
US
Headquarters
5835 Peachtree Corners East
Suite D
Norcross, GA 30092
US
Suite D
Norcross, GA 30092
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||